Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemigatinib in advanced adenosquamous carcinoma of the pancreas
NCT05216120Phase 2Withdrawn
- Sponsor
- HonorHealth Research Institute
- Start
- Jun 2022
- Primary completion
- Aug 2024
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemigatinib in adenosquamous carcinoma of the pancreas (ASCP), sponsored by HonorHealth Research Institute. Primary endpoint: Overall Response Rate. Planned start Jun 2022; status: withdrawn.
02
Drugs
pemigatinib
03
Conditions
adenosquamous carcinoma of the pancreas (ASCP)
Beyond the preview
Go deeper on NCT05216120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05216120.